Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

bioAffinity Technologies, Inc. - Common Stock (NQ:BIAF)

0.2470 +0.0103 (+4.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 858,116
Open 0.2340
Bid (Size) 0.2450 (2)
Ask (Size) 0.2600 (8)
Prev. Close 0.2367
Today's Range 0.2310 - 0.2470
52wk Range 0.1639 - 2.259
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
U.S. Medicine Magazine Spotlights CyPath® Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA
From bioAffinity Technologies
Via Business Wire
bioAffinity Technologies Appoints New Members to Board of Directors
From bioAffinity Technologies, Inc.
Via Business Wire

Performance

YTD
-73.7%
-73.7%
1 Month
-18.7%
-18.7%
3 Month
-18.5%
-18.5%
6 Month
-35.8%
-35.8%
1 Year
-82.2%
-82.2%

More News

Read More
bioAffinity Misses Q2 Revenue Target
Via The Motley Fool
bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports Second Quarter 2025 Results
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales
From bioAffinity Technologies, Inc.
Via Business Wire
Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results
From bioAffinity Technologies, Inc.
Via Business Wire
Case Study: CyPath® Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools
From bioAffinity Technologies, Inc.
Via Business Wire
Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company’s Noninvasive Lung Cancer Diagnostic
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Notification of China Patent Award for Company’s Noninvasive Lung Cancer Diagnostic
From bioAffinity Technologies, Inc.
Via Business Wire
Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging
From bioAffinity Technologies, Inc.
Via Business Wire
Top movers in Thursday's session
Via Chartmill
These stocks are the most active in today's session
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Here are the top movers in Thursday's session.
Via Chartmill
Gapping stocks in Thursday's session
Via Chartmill
bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy
From bioAffinity Technologies, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why RH Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Thursday?
Via Chartmill
bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas’ Leadership Board
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Works With Cardinal Health™ OptiFreight® Logistics to Help Meet Demand for CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire

Frequently Asked Questions

Is bioAffinity Technologies, Inc. - Common Stock publicly traded?
Yes, bioAffinity Technologies, Inc. - Common Stock is publicly traded.
What exchange does bioAffinity Technologies, Inc. - Common Stock trade on?
bioAffinity Technologies, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for bioAffinity Technologies, Inc. - Common Stock?
The ticker symbol for bioAffinity Technologies, Inc. - Common Stock is BIAF on the Nasdaq Stock Market
What is the current price of bioAffinity Technologies, Inc. - Common Stock?
The current price of bioAffinity Technologies, Inc. - Common Stock is 0.2470
When was bioAffinity Technologies, Inc. - Common Stock last traded?
The last trade of bioAffinity Technologies, Inc. - Common Stock was at 09/03/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.